2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | MOLECULAR PHARMACEUTICS Mol. Pharmaceutics (此期刊被最新的JCR期刊SCIE收录) LetPub评分 7.8
59人评分
我要评分
声誉 8.7 影响力 6.8 速度 9.3 | |||||||||||||||||||||||||
期刊ISSN | 1543-8384 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
E-ISSN | 1543-8392 | |||||||||||||||||||||||||
2022-2023最新影响因子 (数据来源于搜索引擎) | 4.9 点击查看影响因子趋势图 | |||||||||||||||||||||||||
实时影响因子 | 截止2024年3月26日:4.444 | |||||||||||||||||||||||||
2022-2023自引率 | 6.10%点击查看自引率趋势图 | |||||||||||||||||||||||||
五年影响因子 | 5 | |||||||||||||||||||||||||
h-index | 110 | |||||||||||||||||||||||||
CiteScore |
| |||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||
期刊官方网站 | https://pubs.acs.org/journal/mpohbp | |||||||||||||||||||||||||
期刊投稿网址 | https://acs.manuscriptcentral.com/acs | |||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足MOLECULAR PHARMACEUTICS的语言要求,还能让MOLECULAR PHARMACEUTICS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被MOLECULAR PHARMACEUTICS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||
是否OA开放访问 | Transformative (TJ转换期刊是订阅式/混合期刊,但是正在积极转为完全开放获取期刊。查看ACS说明。) | |||||||||||||||||||||||||
通讯方式 | AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, USA, DC, 20036 | |||||||||||||||||||||||||
出版商 | American Chemical Society | |||||||||||||||||||||||||
涉及的研究方向 | 医学-药学 | |||||||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||
出版周期 | Monthly | |||||||||||||||||||||||||
出版年份 | 2004 | |||||||||||||||||||||||||
年文章数 | 440点击查看年文章数趋势图 | |||||||||||||||||||||||||
Gold OA文章占比 | 8.42% | |||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 92.05% | |||||||||||||||||||||||||
WOS期刊SCI分区 ( 2022-2023年最新版) | WOS分区等级:1区
| |||||||||||||||||||||||||
中科院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||
中科院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||
中科院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||||||
中科院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1543-8384%5BISSN%5D | |||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均2.0个月 | |||||||||||||||||||||||||
平均录用比例 | 网友分享经验: 约50% | |||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在MOLECULAR PHARMACEUTICS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||||||
收稿范围 | 期刊官网数据: 期刊收录研究方向:建模及模拟辅助药物传输机制探究,配方的分子层面理解,生理条件下的配方性能,涉及到药物、赋形剂和药物输送系统效率的材料学研究,药物递送的新兴技术(包括嗅觉学、精准医学和人工智能) | |||||||||||||||||||||||||
收录体裁 | 期刊官网数据: Research Articles Reviews Perspectives Communications | |||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Targeted Nanodrugs to Destroy the Tumor Extracellular Matrix Barrier for Improving Drug Delivery and Cancer Therapeutic Efficacy Author: Chen, Minglong; Chen, Bin; Ge, Xiaoguang; Ma, Qingjie; Gao, Shi Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 5, pp. 2389-2401. DOI: 10.1021/acs.molpharmaceut.2c00947 PubMed DOI |
2. | Longitudinal MicroSPECT Imaging of Systemic Sclerosis Model Mice with [99mTc]Tc-HYNFA via Folate Receptor Targeting Author: Zhang, Yiren; Wen, Xuejun; Wang, Yanjie; Yang, Xia; Chen, Yingxi; Zeng, Xinying; Li, Yesen; Huang, Jinxiong; Guo, Zhide; Zhang, Xianzhong Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 473-480. DOI: 10.1021/acs.molpharmaceut.2c00717 PubMed DOI |
3. | Novel Oxygen-Dependent Degradable Immunotoxin Regulated by the Ubiquitin-Proteasome System Reduces Nonspecific Cytotoxicity Author: Wei, Min; Chen, Anxiang; Zhang, Jian; Ren, Yuhong Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 90-100. DOI: 10.1021/acs.molpharmaceut.2c00503 PubMed DOI |
4. | ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors Author: Jia, Dianlong; Liu, Huimin; Zheng, Shuhui; Yuan, Dandan; Sun, Ruohan; Wang, Fei; Li, Yang; Li, Hui; Yuan, Fengjiao; Fan, Qing; Zhao, Zhenxiong Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 427-437. DOI: 10.1021/acs.molpharmaceut.2c00708 PubMed DOI |
5. | Myricetin-Loaded Nanomicelles Protect against Cisplatin-Induced Acute Kidney Injury by Inhibiting the DNA Damage-cGAS-STING Signaling Pathway Author: Qi, Xueju; Wang, Jing; Fei, Fengshu; Gao, Xintao; Wu, Xiaochen; Shi, Dayong; Guo, Chuanlong Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 136-146. DOI: 10.1021/acs.molpharmaceut.2c00520 PubMed DOI |
6. | Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPAR alpha-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease Author: Du, Kaiyue; Huang, Xin; Peng, Ankang; Yang, Qinghua; Chen, Du; Zhang, Jianxiang; Qi, Rong Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 159-171. DOI: 10.1021/acs.molpharmaceut.2c00549 PubMed DOI |
7. | Unsaturated Fatty Acid Liposomes Selectively Regulate Glutathione Peroxidase 4 to Exacerbate Lipid Peroxidation as an Adaptable Liposome Platform for Anti-Tumor Therapy Author: Huang, Huan; Chen, Yuling; Yin, Na; Li, Gaojie; Ye, Shanshan; Guo, Ling; Feng, Min Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 290-302. DOI: 10.1021/acs.molpharmaceut.2c00642 PubMed DOI |
8. | 18F-5-FPN: A Specific Probe for Monitoring Photothermal Therapy Response in Malignant Melanoma Author: Wang, Yichun; Li, Mengting; Zhang, Xiao; Ji, Hao; Wang, Wenxia; Han, Na; Li, Huiling; Xu, Xiaodong; Lan, Xiaoli Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 572-581. DOI: 10.1021/acs.molpharmaceut.2c00742 PubMed DOI |
9. | Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy Author: Li, Cong; Fan, Chuizhong; Lu, Shuang; Qiu, Qiujun; Gao, Xin; Yan, Xinyang; Wang, Shuo; Zhao, Bing; Liu, Xinrong; Song, Yanzhi; Deng, Yihui Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 438-450. DOI: 10.1021/acs.molpharmaceut.2c00709 PubMed DOI |
10. | Boosting Type-I and Type-II ROS Production of Water-Soluble Porphyrin for Efficient Hypoxic Tumor Therapy Author: Sun, Han; Guo, Ruihua; Guo, Yanhui; Song, Jitao; Li, Zhiliang; Song, Fengling Journal: MOLECULAR PHARMACEUTICS. 2023; Vol. 20, Issue 1, pp. 606-615. DOI: 10.1021/acs.molpharmaceut.2c00822 PubMed DOI |
|
|
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分: | |
同领域作者分享投稿经验:共64条 (包含回复) |
我来分享 |
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960
增值电信业务经营许可证:沪B2-20211595
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451